LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

HomeStock ListAlnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Closed

151.91 -2.52

Overview

Share price change

24h

Current

Min

151.66

Max

155.81

Key metrics

By Trading Economics

Income

-286M

-138M

Sales

-311M

440M

EPS

-1.1

Profit margin

-31.354

Employees

2,100

EBITDA

-330M

-103M

Recommendations

By TipRanks

Rating Consensus

Buy

12 Months Forecast

+44.69 upside

Dividends

By Dow Jones

Next earnings

2 May 2024

Market Stats

By TradingEconomics

Market Cap

29M

19B

Previous open

154.43

Previous close

151.91

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Alnylam Pharmaceuticals Inc chart

Related News

10 Apr 2024, 22:48 UTC

Major Market Movers
Acquisitions, Mergers, TakeOvers

Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition

10 Apr 2024, 21:40 UTC

Major Market Movers
Acquisitions, Mergers, TakeOvers

Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.

10 Apr 2024, 21:24 UTC

Acquisitions, Mergers, TakeOvers

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update

10 Apr 2024, 20:30 UTC

Top News
Acquisitions, Mergers, TakeOvers

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion

10 Apr 2024, 23:06 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

10 Apr 2024, 23:06 UTC

Market Talk
Earnings

Investors Await Macquarie's FY 2025 Guidance -- Market Talk

10 Apr 2024, 22:57 UTC

Market Talk

Aussie Banks Unlikely to Get Upgrades Out of Earnings Season -- Market Talk

10 Apr 2024, 21:47 UTC

Acquisitions, Mergers, TakeOvers

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update

10 Apr 2024, 21:35 UTC

Top News

Buy the Stock Market's Inflation Freakouts -- Heard on the Street -- Update

10 Apr 2024, 21:09 UTC

Acquisitions, Mergers, TakeOvers

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B -- Update

10 Apr 2024, 21:05 UTC

Market Talk

Mexican Stocks Close Lower; Peso Weakens Against Dollar -- Market Talk

10 Apr 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 Apr 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10 Apr 2024, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 Apr 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10 Apr 2024, 20:46 UTC

Acquisitions, Mergers, TakeOvers

Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal -- IBD

10 Apr 2024, 20:28 UTC

Market Talk

Only CPI Surprise, Big-Spending Budget Can Derail Canada Rate Cut in June -- Market Talk

10 Apr 2024, 20:27 UTC

Top News

Hot Inflation Report Weakens Case for Fed's June Rate Cut -- 8th Update

10 Apr 2024, 20:15 UTC

Acquisitions, Mergers, TakeOvers

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B

10 Apr 2024, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

10 Apr 2024, 20:08 UTC

Market Talk

SPDR Gold Drops Following Inflation Data -- Market Talk

10 Apr 2024, 20:04 UTC

Acquisitions, Mergers, TakeOvers

Alpine Immune Sciences: Vertex Will Acquire Alpine for $65 Per Shr or Approximately $4.9B in Cash, Transaction Approved by Both Boards of Directors, Anticipated to Close in 2Q >ALPN

10 Apr 2024, 20:03 UTC

Acquisitions, Mergers, TakeOvers

Vertex Subsidiary Will Commence Cash Tender Offer to Purchase All Alpine Common Stk >VRTX

10 Apr 2024, 20:03 UTC

Acquisitions, Mergers, TakeOvers

Vertex: Alpine Is Strategic Fit and Furthers Use of Scientific Innovation to Create Transformative Medicines Targeting Serious Diseases With High Unmet Need in Specialty Markets >VRTX

10 Apr 2024, 20:02 UTC

Acquisitions, Mergers, TakeOvers

Vertex: Transaction Was Unanimously Approved by Both the Vertex and Alpine Boards

10 Apr 2024, 20:01 UTC

Acquisitions, Mergers, TakeOvers

Vertex Pharmaceuticals Will Acquire Alpine for $65 Per Shr or About $4.9 B in Cash >VRTX ALPN

10 Apr 2024, 20:01 UTC

Acquisitions, Mergers, TakeOvers

Vertex Enters Into Agreement To Acquire Alpine Immune Sciences >VRTX ALPN

10 Apr 2024, 20:01 UTC

Acquisitions, Mergers, TakeOvers

Vertex Enters Into Agreement To Acquire Alpine Immune Sciences >VRTX ALPN

10 Apr 2024, 19:58 UTC

Market Talk

Markets Largely Ignored BOC's Macklem's Remark on Possible June Cut -- Market Talk

10 Apr 2024, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Eke Out Gains Ahead of Storage Report -- Market Talk

Peer Comparison

Price change

Alnylam Pharmaceuticals Inc forecast

Price Target

By TipRanks

44.69% upside

12 Months Forecast

Average 222.18 USD  44.69%

High 395 USD

Low 144 USD

Based on 20 Wall Street analysts offering 12 month price targets for Alnylam Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

20 ratings

12

Buy

8

Hold

0

Sell

Technical Score

By Trading Central

150.81 / 156.04 Support&Resistance

Short Team

Strong Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational RNAi therapeutics are focused in four Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and CNS/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO (patisiran) is an intravenously administered RNAi therapeutic targeting Transthyretin Amyloidosis (TTR). The GIVLAARI (givosiran) is used to reduce induced liver aminolevulinic acid synthase 1 mRNA, to reduction of toxins associated with attacks and other disease manifestations of Acute Hepatic Porphyria (AHP). The OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of Primary Hyperoxaluria Type 1 (PH1). The Leqvio (inclisiran) is used for the treatment of adults with hypercholesterolemia.